VERTEX PHARMACEUTICALS INC / MA (VRTX) Operating income 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) annual operating income history from SEC filings — each fiscal year as reported.
$4.2BFY2025 · since FY2016: $9.9M → $4.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $4.2B | +1891.9% |
| FY2024 | -$232.9M | -106.1% |
| FY2023 | $3.8B | -11.0% |
| FY2022 | $4.3B | +54.8% |
| FY2021 | $2.8B | -2.6% |
| FY2020 | $2.9B | +138.5% |
| FY2019 | $1.2B | +88.5% |
| FY2018 | $635.1M | +415.4% |
| FY2017 | $123.2M | +1140.4% |
| FY2016 | $9.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Gross marginVRTX Operating marginVRTX Operating cash flowVRTX Free cash flowVRTX Capital expendituresVRTX Return on equityVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →